Trials / Terminated
TerminatedNCT02042885
A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 79 (estimated)
- Sponsor
- Otsuka Novel Products GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the tolerability profile of OPB-111001 and to determine the most suitable dose of OPB-111001 in patients with advanced cancer
Conditions
- Prostate Cancer
- Salivary Gland Cancer
- Endometrial Cancer
- Squamous Cell Carcinoma of the Cervix
- Breast Cancer
- Ovarian Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OPB-111001 |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2014-01-23
- Last updated
- 2015-10-20
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02042885. Inclusion in this directory is not an endorsement.